Pan-Cancer Analysis of Disulfidptosis-Related Genes Affecting Prognosis and Tumor Microenvironment

• Published in: Zhongliu fangzhi yanjiu Vol. 52; no. 1; pp. 52 - 61
• Main Authors: Sun, Jingyang, Jiang, Rongxuan, Hou, Liren, Dong, Huanhuan, Lin, Yihan, Dong, Niuniu, Zhang, Guangjian, Zhang, Yanpeng
• Format: Journal Article
• Language: Chinese; English
• Published: Tianjin China Anti-Cancer Association 01.01.2025; Magazine House of Cancer Research on Prevention and Treatment
• Subjects: Adenocarcinoma; Algorithms; Bioinformatics; Biomarkers; Cancer; disulfidptosis-related gene; drug sensitivity; Esophageal carcinoma; Genes; Hepatocellular carcinoma; Immune system; Liver cancer; Lung carcinoma; Lungs; pan-cancer analysis; PD-1 protein; PD-L1 protein; Prognosis; Renal cell carcinoma; Sensitivity analysis; Stromal cells; Tumor microenvironment; Tumors
• ISSN: 1000-8578
• DOI: 10.3971/j.issn.1000-8578.2025.24.0302

Objective To assess the potential role of disulfidptosis-related genes (DRGs) in pan-cancer on prognosis and immunity on the basis of bioinformatics approaches. Methods Pan-cancer RNA-seq data, mutation profiles, clinical information, TMB, MSI, stemness scores, and tumor and immune microenvironment data contained in TCGA and various open-source online databases, and multi-group R-language algorithms were used for comprehensive analysis. The expression levels of DRGs at the cellular level were experimentally validated using qPCR. Results LRPPRC, NCKAP1, NDUFS1, and NUBPL had a better prognosis in renal clear cell carcinoma (P<0.001), whereas SLC7A11, NCKAP1, and SLC3A2 had a worse prognosis in hepatocellular carcinoma (P<0.001). TME analysis showed that LRPPRC was negatively correlated with immune cells, stromal cells, and estimated scores in all tumor types. TMB analysis revealed the potential research value of DRGs for PD-1/PD-L1 therapy in pan-cancer. Drug sensitivity analysis showed that SLC7A11 (r=0.454), SLC3A2 (r=0.366), and NCKAP1 (r=0.455) were significantly associated with Kahalide F (P<0.01). Experimental validation demonstrated the overall higher expression levels of GYS1 and NCKAP1 than normal cells in lung adenocarcinoma, colon adenocarcinoma, esophageal squamous carcinoma, and hepatocellular carcinoma (P<0.05). Conclusion Pan-cancer analysis of DRGs indicates that DRGs may serve as important biomarkers for the diagnosis and prognosis of renal clear-cell carcinoma, lung adenocarcinoma, and hepatocellular carcinoma.